BrUOG 390: Neoadjuvant Treatment With Talazoparib

BrUOG 390: Neoadjuvant Treatment With Talazoparib
Conditions:   BRCA1 Mutation;   BRCA2 Mutation;   Ovarian Cancer;   Fallopian Tube Cancer;   High Grade Serous Carcinoma
Intervention:   Drug: Talazoparib Oral Capsule
Sponsors:   Brown University;   Pfizer;   Lifespan

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 21, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine